NCT06653842Phase 2Active not recruiting

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

Study sponsor: Palvella Therapeutics, Inc. · PVLA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-21Actual
Enrollment · participants15Estimated
Source updated2026-03-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 21 Nov 2025.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview